Q1 2025 AbbVie Inc Earnings Call Transcript
Key Points
- AbbVie Inc (ABBV) exceeded expectations with first-quarter adjusted earnings per share of $2.46, which is $0.10 above the guidance midpoint.
- Total net revenues were more than $13.3 billion, nearly $550 million ahead of expectations, driven by strong performance across multiple therapeutic areas.
- The ex-Humira platform delivered robust sales growth of more than 21%, with significant contributions from immunology, neuroscience, oncology, and aesthetics.
- Skyrizi and Rinvoq showed exceptional performance, contributing $5.1 billion in combined sales this quarter, reflecting growth of more than 65%.
- AbbVie Inc (ABBV) raised its full-year adjusted earnings per share guidance by $0.10, now expecting adjusted EPS between $12.09 and $12.29.
- Global sales of Humira were down 49.5% on an operational basis, primarily due to faster share erosion from biosimilar competition.
- Aesthetics global sales were down 10.2% on an operational basis, with Botox cosmetic revenues down 10.7% and Juvederm sales down 20%, impacted by economic headwinds.
- The company is moderating its assumptions for category growth globally in aesthetics due to a decline in recent consumer sentiment.
- Imbruvica global sales were down 11.9%, reflecting competitive dynamics in chronic lymphocytic leukemia (CLL).
- AbbVie Inc (ABBV) faces potential risks from sectoral tariffs and other trade policy shifts, which have not been included in the current guidance.
Welcome to the AbbVie first-quarter 2025 earnings conference call. (Operator instructions) As a reminder, this call is being recorded.
I would now like to introduce Ms. Shea, Senior Vice President, Investor Relations.
Good morning, and thanks for joining us. Also on the call with me today are Rob Michael, Chief Executive Officer; Jeff Stewart, Executive Vice President, Chief Commercial Officer; Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer; and Scott Reents, Executive Vice President, Chief Financial Officer.
Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
